1. Home
  2. RNTX vs IDN Comparison

RNTX vs IDN Comparison

Compare RNTX & IDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.79

Market Cap

65.3M

Sector

Health Care

ML Signal

HOLD

Logo Intellicheck Inc.

IDN

Intellicheck Inc.

HOLD

Current Price

$2.42

Market Cap

56.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNTX
IDN
Founded
2001
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
65.3M
56.5M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
RNTX
IDN
Price
$0.79
$2.42
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$10.00
$7.33
AVG Volume (30 Days)
367.2K
294.2K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
44.16
220.00
EPS
N/A
0.06
Revenue
N/A
$4,433,454.00
Revenue This Year
N/A
$12.54
Revenue Next Year
N/A
$15.32
P/E Ratio
N/A
$39.17
Revenue Growth
N/A
23.21
52 Week Low
$0.69
$2.33
52 Week High
$2.18
$9.08

Technical Indicators

Market Signals
Indicator
RNTX
IDN
Relative Strength Index (RSI) 51.60 N/A
Support Level $0.71 N/A
Resistance Level $0.88 N/A
Average True Range (ATR) 0.06 0.00
MACD 0.00 0.00
Stochastic Oscillator 41.20 0.00

Price Performance

Historical Comparison
RNTX
IDN

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About IDN Intellicheck Inc.

Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.

Share on Social Networks: